It is worth noting that although the microbiome composition is beginning to be seen as a predictive biomarker for immunotherapy, a combination of multiple biomarkers could be better to predict the efficacy of this treatment, as for now none of the biomarkers studied—PDL1, tumor mutational burden, tumor infiltrating lymphocytes—possesses high enough sensitivity and specificity to predict response rate [99]. Here, CD274 is linked to neoplasm.